Published in Br J Clin Pharmacol on November 10, 2006
The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol (2009) 2.26
Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol (2013) 1.03
Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pages. Br J Clin Pharmacol (2012) 0.93
Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Front Pharmacol (2014) 0.90
Adverse drug reactions--no farewell to harms. Br J Clin Pharmacol (2007) 0.85
Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol (2014) 0.82
The effects of moxifloxacin on QTc interval in healthy Korean male subjects. Drugs R D (2014) 0.81
Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events. PLoS One (2016) 0.78
Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update. Drug Saf (2015) 0.77
Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects. Drug Des Devel Ther (2015) 0.76
Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects. PLoS One (2015) 0.75
Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study. Br J Clin Pharmacol (2015) 0.75
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet (1982) 6.06
Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry (2001) 5.16
Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A (2005) 4.14
Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm (2004) 3.15
Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc (2003) 2.69
Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol (1992) 2.63
Electrocardiographic findings in a healthy biracial population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Cardiol (1998) 2.31
Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation (1996) 2.13
A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res (2003) 1.89
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J (1986) 1.74
Electrocardiographic quantitation of ventricular repolarization. Circulation (1989) 1.65
Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol (2004) 1.48
Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther (1998) 1.38
QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther (2003) 1.34
Early repolarization on scalar electrocardiogram. Am J Med Sci (1995) 1.33
Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation (2002) 1.30
Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther (2000) 1.11
Single nucleotide polymorphism map of five long-QT genes. J Mol Med (Berl) (2004) 1.07
Effects of adrenaline and potassium on QTc interval and QT dispersion in man. Eur J Clin Invest (2003) 1.04
Characterization of a novel Long QT syndrome mutation G52R-KCNE1 in a Chinese family. Cardiovasc Res (2003) 1.03
The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther (1994) 0.98
Ethnic differences in electrocardiographic intervals and axes. J Electrocardiol (2001) 0.95
Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther (2005) 0.94
Antipsychotic drugs and QT interval prolongation. Psychiatr Q (2003) 0.94
Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol (1995) 0.93
Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy. Heart (2002) 0.92
Prevalence and risk factors for prolonged QTc in a multiethnic cohort in rural Hawaii. Clin Biochem (2005) 0.90
Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol (1999) 0.88
Blood quinidine levels and cardiac effects in white British and Nigerian subjects. Br J Clin Pharmacol (1982) 0.84
Are there sex-specific differences in ventricular repolarization or in drug-induced early afterdepolarizations in isolated rabbit purkinje fibers? J Cardiovasc Pharmacol (2000) 0.84
Twenty single-nucleotide polymorphisms in four genes encoding cardiac ion channels. J Hum Genet (2002) 0.78
Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. Pharmacol Ther (1983) 0.78
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med (2004) 3.64
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A (2007) 3.24
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
An estimation of right- and left-sided central venous catheter insertion depth using measurement of surface landmarks along the course of central veins. Anesth Analg (2011) 2.89
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry (2007) 2.26
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol (2011) 2.09
Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage. Sci Signal (2012) 2.07
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci (2005) 1.97
Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm (2006) 1.97
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res (2010) 1.74
The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol (2007) 1.73
Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther (2002) 1.69
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology (2007) 1.64
R-Spondin1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical Wnt/beta-catenin pathway. Proc Natl Acad Sci U S A (2009) 1.63
QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf (2005) 1.63
Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. Med Care (2007) 1.60
HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology (2008) 1.60
Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J Nutr (2006) 1.59
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
Clinical outcomes and the risk factors of coronary artery aneurysms that developed after drug-eluting stent implantation. Circ J (2011) 1.55
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology (2012) 1.50
Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther (2006) 1.50
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Prognostic value of creatine kinase-myocardial band isoenzyme elevation following percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv (2012) 1.44
Meta-analysis of three randomized trials and nine observational studies comparing drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery disease. Am J Cardiol (2012) 1.43
CatSperbeta, a novel transmembrane protein in the CatSper channel complex. J Biol Chem (2007) 1.43
Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res (2006) 1.41
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. J Cell Sci (2009) 1.41
QTc interval prolongation associated with intravenous methadone. Pain (2003) 1.40
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol (2012) 1.39
Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacol (2003) 1.37
In silico identification of the key components and steps in IFN-gamma induced JAK-STAT signaling pathway. FEBS Lett (2005) 1.37
The biphasic behavior of incoherent feed-forward loops in biomolecular regulatory networks. Bioessays (2008) 1.37
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Coupled feedback loops form dynamic motifs of cellular networks. Biophys J (2007) 1.32
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist (2006) 1.30
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med (2003) 1.28
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol (2009) 1.28
Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol (2011) 1.27
Quantitative analysis of robustness and fragility in biological networks based on feedback dynamics. Bioinformatics (2008) 1.26
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum (2004) 1.25
Modeling and simulation of intracellular dynamics: choosing an appropriate framework. IEEE Trans Nanobioscience (2004) 1.25
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther (2005) 1.24
Coupled positive and negative feedback circuits form an essential building block of cellular signaling pathways. Bioessays (2007) 1.24
Cooperative activation of PI3K by Ras and Rho family small GTPases. Mol Cell (2012) 1.23
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat (2008) 1.21
Clinical characteristics of stent fracture after sirolimus-eluting stent implantation. Int J Cardiol (2008) 1.21
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy (2010) 1.21
Collecting duct carcinoma of the kidney: CT and pathologic correlation. Eur J Radiol (2005) 1.20
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat (2009) 1.20
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol (2010) 1.18
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.17
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res (2010) 1.14
Coherent coupling of feedback loops: a design principle of cell signaling networks. Bioinformatics (2008) 1.14
Inferring gene regulatory networks from temporal expression profiles under time-delay and noise. Comput Biol Chem (2007) 1.12
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther (2005) 1.11
R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression. FEBS Lett (2008) 1.11
Potential drug-drug interactions within Veterans Affairs medical centers. Am J Health Syst Pharm (2007) 1.11
Identification of small scale biochemical networks based on general type system perturbations. FEBS J (2005) 1.11
Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer (2007) 1.10
A novel, single, transmembrane protein CATSPERG is associated with CATSPER1 channel protein. Biol Reprod (2009) 1.10
In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos (2010) 1.10
Novel diagnostic catheter specifically designed for both coronary arteries via the right transradial approach. A prospective, randomized trial of Tiger II vs. Judkins catheters. Int J Cardiovasc Imaging (2005) 1.10
Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther (2004) 1.09